ISDA: 3V9T

Deposition Date 2011-12-28

Release Date 2012-02-01

Last Version Date 2023-11-08

Entry Detail

PDB ID:

3V9T

Keywords:

TRANSCRIPTION/TRANSCRIPTION REGULATOR

Title:

Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator

Biological Source:

Source Organism(s):

Homo sapiens (Taxon ID: 9606)

Expression System(s):

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.65 Å

R-Value Free:

0.21

R-Value Work:

0.20

R-Value Observed:

0.20

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Peroxisome proliferator-activated receptor gamma
Gene (Uniprot):PPARG
Chain IDs:A
Chain Length:283
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P37231 Pfam ID:PF00104

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Peptide from Peroxisome proliferator-activated receptor gamma coactivator 1-alpha
Gene (Uniprot):PPARGC1A
Chain IDs:B (auth: C)
Chain Length:19
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q9UBK2

Ligand Molecules

17L

Primary Citation

Substituents at the naphthalene C3 position of (-)-Cercosporamide derivatives significantly affect the maximal efficacy as PPAR(gamma) partial agonists

Furukawa, A, Arita, T, Fukuzaki, T, Satoh, S, Mori, M, Honda, T, Matsui, Y, Wakabayashi, K, Hayashi, S, Araki, K, Ohsumi, J.Show

Bioorg.Med.Chem.Lett. 22 1348 1351 (2012)

PMID: 22225641 DOI: 10.1016/j.bmcl.2011.12.066

Abstact

Peroxisome proliferator-activated receptor gamma (PPARγ) is a potential drug target for treating type 2 diabetes. The selective PPARγ modulators (SPPARMs), which partially activate the PPARγ transcriptional activity, are considered to improve the plasma glucose level with attenuated PPARγ related adverse effects. However, the relationships between desired pharmacological profiles and ligand specific PPARγ transcriptional profiles have been unclear. And there is also little knowledge of how to control ligand specific PPARγ transcriptional profiles. Herein, we present synthesis of novel derivatives containing substituent at naphthalene C3 position of compound 1. The novel derivatives showed various maximal efficacies as PPARγ partial agonist.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form